secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001193125-24-257205
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design
--------------------------------------------------------------------------------

- Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.
- High dose TSHA-102 well tolerated; no SAEs or DLTs in 2 adolescent/adult and 1 pediatric patient.
- FDA aligned on trial design, endpoints, and natural history dataset for Part B of REVEAL trials.
- FDA approved pivotal TSHA-102 product manufactured with final commercial manufacturing process for REVEAL trials.
- Safety and efficacy data from high dose cohorts of both REVEAL trials expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/0001193125-24-257205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-257205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer